診断用特殊抗体市場- 世界の産業規模、シェア、動向、機会、予測、抗体別、用途別、エンドユーザー別、地域別、競合別、2020～2030年

診断用特殊抗体の世界市場規模は2024年に279億3,000万米ドルで、予測期間中のCAGRは5.13%で2030年には334億5,000万米ドルに達すると予測されています。

診断用特殊抗体の世界市場とは、診断検査やアッセイに使用され、患者の特定の疾患や状態、バイオマーカーを検出するための特殊な抗体の市場を指します。これらの抗体は診断アッセイの重要な構成要素であり、様々な疾患や状態を正確かつ高感度に検出する上で重要な役割を果たしています。製薬会社やバイオテクノロジー企業は、新規の診断アッセイや特殊抗体の開発に投資し、市場の提供を拡大しています。2022年1月、バイオ・ラッド・ラボラトリーズ社は、ペルツズマブ（ペルジェタ）に対して卓越した特異性を示す4種類の阻害抗体を発表しました。容易に入手可能なこれらの抗体は、ペルツズマブの標的であるヒト上皮成長因子2（HER2）への結合を阻害するように設計されており、研究者は高精度で高感度なアッセイを作成することができます。これらのアッセイは、診断目的、生物学的分析、医薬品の領域におけるペルツズマブおよびそのバイオシミラーのモニタリングに用いることができます。特殊抗体に依存する診断検査は、慢性疾患を発症するリスクのある個人を特定し、予防的介入を可能にするために不可欠です。世界の高齢化により、慢性疾患にかかりやすくなっています。高齢者人口の増加に伴い、加齢に関連した健康課題に対処できる診断ツールの需要も増加しています。

市場促進要因

慢性疾患の増加

主な市場課題

開発・生産コスト

主要市場動向

ポイントオブケア検査の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の診断用特殊抗体市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 抗体別（モノクローナル抗体、ポリクローナル抗体、組み換えポリクローナル抗体）
  • 用途別（デング熱診断、HIV診断、肝炎診断、感染症診断、腫瘍診断、結核診断）
  • エンドユーザー別（診断研究所、病院、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の診断用特殊抗体市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の診断用特殊抗体市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の診断用特殊抗体市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の診断用特殊抗体市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの診断用特殊抗体市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Diagnostic Specialty Antibodies Market was valued at USD 27.93 Billion in 2024 and is expected to reach USD 33.45 Billion by 2030 with a CAGR of 5.13% during the forecast period. The Global Diagnostic Specialty Antibodies Market refers to the market for specialized antibodies used in diagnostic tests and assays to detect specific diseases, conditions, or biomarkers in patients. These antibodies are crucial components of diagnostic assays and play a vital role in the accurate and sensitive detection of various diseases and conditions. Pharmaceutical and biotechnology companies are investing in the creation of novel diagnostic assays and specialty antibodies, expanding the market's offerings. Governments and healthcare organizations are increasingly focusing on preventive healthcare measures in January 2022, Bio-Rad Laboratories, Inc. introduced four inhibitory antibodies that exhibit exceptional specificity towards pertuzumab (Perjeta). These readily available antibodies are designed to impede the binding of pertuzumab to its target, the human epidermal growth factor 2 (HER2), thus enabling researchers to create highly precise and sensitive assays. These assays can be employed for diagnostic purposes, bioanalysis, and the monitoring of pertuzumab and its biosimilars in the realm of pharmaceuticals. Diagnostic tests that rely on specialty antibodies are essential for identifying individuals at risk of developing chronic diseases, enabling preventive interventions. The global aging population is more susceptible to chronic diseases. As the elderly population grows, so does the demand for diagnostic tools capable of addressing age-related health challenges.

Key Market Drivers

Rising Incidence of Chronic Diseases

The world is witnessing an alarming increase in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and autoimmune conditions. This global health challenge has catalyzed a growing demand for precise and early diagnostic tools. In response, the Global Diagnostic Specialty Antibodies Market has emerged as a vital player in the healthcare sector. Chronic diseases have become a defining health issue of our time. In 2021, noncommunicable diseases (NCDs) were responsible for at least 43 million fatalities, accounting for 75% of global deaths unrelated to the pandemic. These conditions pose not only a significant threat to human health but also an economic burden on healthcare systems worldwide.

Diagnostic specialty antibodies, also known as immunoassays, are an integral part of modern diagnostic medicine. They are designed to detect specific biomarkers, antigens, or antibodies in patient samples, enabling accurate disease identification and monitoring. Chronic diseases are often asymptomatic in their early stages. Diagnostic specialty antibodies allow for the early detection of disease markers, facilitating timely interventions and treatment. This capability is crucial in improving patient outcomes and reducing the overall healthcare burden. The trend toward personalized medicine emphasizes treatments tailored to an individual's genetic makeup, lifestyle, and the specific characteristics of their disease. Diagnostic specialty antibodies play a pivotal role in identifying biomarkers that guide treatment decisions, ensuring that patients receive the most effective therapies. Many chronic diseases require ongoing monitoring to assess treatment efficacy and disease progression. Diagnostic specialty antibodies enable healthcare providers to track changes in biomarker levels, helping them make informed decisions about treatment adjustments. The increasing incidence of chronic diseases has prompted extensive research and development efforts in the field of diagnostics.

Early diagnosis of chronic diseases not only saves lives but also reduces the long-term healthcare costs associated with advanced disease management. Diagnostic specialty antibodies contribute significantly to this cost-saving aspect. Emerging economies in Asia-Pacific, Latin America, and Africa are experiencing rapid urbanization and improvements in healthcare infrastructure. This has led to increased access to diagnostic services and an expanding market for diagnostic specialty antibodies.

Key Market Challenges

Cost of Development and Production

The development and production of diagnostic specialty antibodies involve substantial financial investments, making cost a critical challenge in this market. The process begins with extensive research and development (R&D), where scientists identify and validate target antigens, followed by antibody generation, screening, and optimization. These initial stages require sophisticated laboratories, skilled personnel, and expensive reagents, significantly driving up costs. Producing high-quality, specific antibodies involves rigorous testing to ensure sensitivity, specificity, and reproducibility, further adding to the financial burden.

Manufacturing diagnostic specialty antibodies at scale demands advanced bioprocessing techniques, such as hybridoma technology or recombinant DNA methods, which require specialized equipment and stringent quality control measures. The purification and characterization of antibodies involve high costs due to the need for sophisticated chromatography systems and analytical tools. Good Manufacturing Practice (GMP) compliance adds another layer of cost, as regulatory agencies mandate strict quality assurance protocols throughout production.

These high production costs often translate into expensive end-user pricing, potentially restricting access to these essential diagnostic tools, especially in low- and middle-income countries with budget-constrained healthcare systems. the need for continuous innovation to enhance antibody performance further increases development expenses. Companies must balance investment in innovation with cost-effective production strategies to remain competitive while ensuring broader market accessibility. As a result, manufacturers are exploring alternative production approaches, such as plant-based antibody production and cell-free synthesis, to reduce costs and improve scalability. Despite these efforts, cost remains a significant barrier that impacts pricing, market expansion, and accessibility in the global diagnostic specialty antibodies market.

Key Market Trends

Expansion of Point-of-Care Testing

The expansion of point-of-care testing (POCT) is revolutionizing diagnostics by enabling rapid, decentralized testing that can be conducted at or near the patient's location. This shift reduces the dependency on centralized laboratories, facilitating quicker decision-making in clinical settings such as hospitals, physician offices, and even home-based care. POCT is particularly beneficial in emergency scenarios where immediate test results are necessary for timely medical interventions. Diagnostic specialty antibodies play a crucial role in POCT devices, as they are used in lateral flow assays, immunoassays, and other rapid detection platforms. The rising prevalence of infectious diseases, chronic conditions, and the demand for personalized healthcare are driving innovations in antibody-based POCT solutions. With ongoing advancements, POCT is expanding beyond conventional applications like glucose monitoring and pregnancy tests to more complex disease detection, including cardiac biomarkers, infectious disease screening, and oncology markers.

The growing focus on decentralized healthcare models, particularly in remote and resource-limited settings, is fueling the demand for rapid and reliable diagnostic solutions. The integration of POCT with digital health platforms and connectivity solutions enhances real-time monitoring and data sharing, improving patient outcomes and streamlining clinical workflows. The combination of artificial intelligence (AI) and POCT is also optimizing test interpretation, further driving the accuracy and efficiency of diagnostic specialty antibody-based assays.

As POCT continues to evolve, regulatory agencies are supporting its development through streamlined approval processes and quality assurance standards. Companies in the diagnostic specialty antibodies market are actively investing in research and development to enhance the sensitivity, specificity, and affordability of antibody-based POCT devices. In February 2022, Abcam and Twist Bioscience Corporation announced a licensing agreement under which Abcam will leverage Twist's proprietary VHH phage library for antibody discovery, development, and commercialization, with a focus on diagnostics and research applications. The continued expansion of POCT will significantly contribute to the growth of the global diagnostic specialty antibodies market, making diagnostics more accessible, efficient, and patient-centric.

Key Market Players

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

Report Scope:

In this report, the Global Diagnostic Specialty Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diagnostic Specialty Antibodies Market, By Antibody:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Polyclonal Antibodies

Diagnostic Specialty Antibodies Market, By Application:

• Dengue Diagnostics
• HIV Diagnostics
• Hepatitis Diagnosis
• Infectious Disease Diagnostics
• Oncology Diagnostics
• Tuberculosis Diagnostics

Diagnostic Specialty Antibodies Market, By End User:

• Diagnostic Laboratories
• Hospitals
• Others

Diagnostic Specialty Antibodies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diagnostic Specialty Antibodies Market.

Available Customizations:

Global Diagnostic Specialty Antibodies market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diagnostic Specialty Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Antibody (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies)
  • 5.2.2. By Application (Dengue Diagnostics, HIV Diagnostics, Hepatitis Diagnosis, Infectious Disease Diagnostics, Oncology Diagnostics, Tuberculosis Diagnostics)
  • 5.2.3. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Diagnostic Specialty Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Antibody
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diagnostic Specialty Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Antibody
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Diagnostic Specialty Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Antibody
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Diagnostic Specialty Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Antibody
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Diagnostic Specialty Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Antibody
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Diagnostic Specialty Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Antibody
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Diagnostic Specialty Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Antibody
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Diagnostic Specialty Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Antibody
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Diagnostic Specialty Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Antibody
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Diagnostic Specialty Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Antibody
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Diagnostic Specialty Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Antibody
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Diagnostic Specialty Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Antibody
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Diagnostic Specialty Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Antibody
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Diagnostic Specialty Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Antibody
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Diagnostic Specialty Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Antibody
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Diagnostic Specialty Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Antibody
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Diagnostic Specialty Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Antibody
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Diagnostic Specialty Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Antibody
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Diagnostic Specialty Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Antibody
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Diagnostic Specialty Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Antibody
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Diagnostic Specialty Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Antibody
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Diagnostic Specialty Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Antibody
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Diagnostic Specialty Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Antibody
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Diagnostic Specialty Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Antibody
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User
  • 10.3.4. Kuwait Diagnostic Specialty Antibodies Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Antibody
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Abcam Limited
• 14.3. Abbott Laboratories Inc
• 14.4. Bio-Rad Laboratories Inc
• 14.5. Agilent Technologies Inc
• 14.6. Creative Diagnostics
• 14.7. Thermo Fisher Scientific Inc
• 14.8. Becton Dickinson & Company
• 14.9. Merck KGaA
• 14.10. Sartorius AG

15. Strategic Recommendations

16. About Us & Disclaimer